Life Sciences & Pharmaceuticals Symposium
Amber Salzman, Ph.D. was appointed president and chief executive officer of Adverum in
October 2016 after joining the company earlier in the year as president and chief
operating officer after the merger of Annapurna Therapeutics with Avalanche
Biotechnologies. Dr. Salzman was the president and chief executive officer of Annapurna
Therapeutics between 2012 and 2016. Dr. Salzman has served in leadership roles at large
pharmaceutical companies, small pharmaceutical companies, and in the rare disease
community, including her role as chief executive officer of Cardiokine Inc. prior to its
acquisition by Cornerstone Therapeutics, Inc. in 2011. Dr. Salzman had a 25-year career
at GlaxoSmtihKline plc, where she served as a member of the R&D executive team,
leading drug development projects and clinical trials in more than 30,000 patients
worldwide. Since 2001, Dr. Salzman has served as president of the Stop ALD Foundation,
a patient-advocacy group seeking improvements in treatments for patients with
adrenoleukodystrophy (ALD), and played a key role in developing a lentiviral gene therapy
treatment for this disease. Dr. Salzman received a B.A. in Computer Science from Temple
University and a Ph.D. in Mathematics from Bryn Mawr College.
Bernard Munos, M.B.A., M.S., is a Senior Fellow at FasterCures, a center of the Milken Institute, and the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Before that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. He is also a member of the Forum on Drug Discovery, Development, and Translation at the National Academy of Medicine; a member of the Advisory Board of Science Translational Medicine; a non-executive Director of Glenmark Pharmaceuticals; a Board member or Advisor to a dozen other companies or publicly-financed research organizations; and a former member of the Advisory Council of the National Institutes of Health’s National Center for Translational Sciences (NCATS). His research has been profiled by Forbes magazine; and the popular industry newsletter FiercePharma named him one of the 25 most influential people in biopharma. He received his MBA from Stanford University, and holds other graduate degrees in animal science and agricultural economics from the Paris Institute of Technology for Life, Food and Environmental Sciences and the University of California, Davis. He blogs about biomedical innovation on the Forbes website.
CARL SPANA, Ph.D., co-founder of Palatin, has been the Chief Executive Officer and President since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly-held pharmaceutical company, where he was involved in scientific research in the field of immunology. He was previously a member of the board of the life science company AVAX Technologies, Inc.
Dr. Spana received his Ph.D. in molecular biology from the Johns Hopkins University and his B.S. in biochemistry from Rutgers University.
Eddie Moradian received his PhD in biotechnology from the Swiss Federal Institute in Zurich, Switzerland. Since 1987, he has been a founder or co-founder of a series of companies in the biotechnological, pharmaceutical and diagnostic industries with presence in Europe, US and Israel.
At MD Biosciences, he leads a group of companies, each individually focused on drug development, preclinical contract research services, CLIA clinical biomarker diagnostic services, and early stage investment in other promising, emerging companies.
Most recently, Eddie was a co-founder of and is serving as co-CEO of Incubology, LLC, a state of the art multi-technological incubator facility with over 50,000sqf of built, turn-key ready laboratory and high tech space located near Saint Paul, MN.
Ezio Bonvini, MD, is the Senior VP of Research & CSO at MacroGenics, Inc. A physician by training, he is an expert in immunobiology and has authored numerous publications in the field. He joined MacroGenics in June 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics Evaluation and Research (FDA), where he served as Chief of the Laboratory of Immunobiology and Acting Deputy Director of the Division of Monoclonal Antibodies.
Gary Jacob, Ph.D., is Co-Founder, Chairman and Chief Executive Officer of Synergy Pharmaceuticals Inc., a public biopharmaceutical company which is listed on Nasdaq (NASDAQ: SGYP), and based in New York City, with research, technical operations and commercial offices in suburban Philadelphia. The Company is focused on the development and commercialization of novel gastrointestinal (GI) therapies, and recently launched its first commercial product, TRULANCETM (plecanatide), in the U.S. for treatment of adults with chronic idiopathic constipation. Dr. Jacob has served as the President, Chief Executive Officer and a Director at Synergy Pharmaceuticals Inc. since July 2008. He is a co-inventor of TRULANCE, and has over 30 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and drug development, operations and business development. Dr. Jacob has led Synergy Pharmaceuticals from an early-stage development company, with market capitalization of approximately $100 million, to its present-day capitalization of over $ 1 billion, during which time the Company has raised over $675 million. Dr. Jacob has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. He also serves as a director of Trovagene, Inc., a public Nasdaq-listed precision medicine company, and is Chairman of the Board of ContraVir Pharmaceuticals, Inc., a public Nasdaq-listed antiviral company, since May 2013. He served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology, and was a Monsanto Science Fellow, specializing in the field of glycobiology and drug discovery. From 1986 to 1990, he managed the G.D. Searle Glycobiology Group located at Oxford University, England. Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, St. Louis, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.
James Noble has served as Adaptimmune’s full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one of its co-founders. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore Limited. Mr. Noble has 24 years of experience in the biotech industry.
He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc (NASDAQ: GWPH).
Mr. Noble qualified as a chartered accountant with PwC and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was Adaptimmune’s predecessor, from 2000 to 2006. Mr. Noble holds an MA from the University of Oxford.
Jeffrey Wolf is the founder and CEO of Heat Biologics. He was formerly the founder and managing director at Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies based upon novel research breakthroughs.
Throughout his career Mr. Wolf has created life science startup companies and actively supported the growth of these companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ-listed gene therapy company; TyRx Pharma (co-founder and Chairman) which was focused on the development of novel bio-compatible polymers and recently sold to Medtronic; EluSys Therapeutics (founder and CEO), focused on the development of novel antibodies against infectious diseases and GenerationOne (founder and CEO), focused on mobile-based healthcare solutions.
Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics.
Jonathan Peacock is the Chairman of Bellerophon Therapeutics and Chairman of Arix Bioscience, Ltd. He was the former CFO of Amgen Inc. based in California and prior to that CFO of the Pharmaceuticals Division of Novartis AG, based in Switzerland. Before joining the pharma industry, Jon was a partner at McKinsey and Co, where he was co-head of the European Corporate Finance practice, and was also a partner at Price Waterhouse in London and New York from 1993-98. He is a graduate of the University of St Andrews in Scotland.
Matthew L. Plaud is an accomplished executive with over twenty years of experience in a highly regulated environment. Currently he is the CEO of SOTIO, LLC, the North American arm of the SOTIO Group. In his three years with SOTIO, he has risen through the ranks from starting as the Director of Apheresis Network Management, to taking on all aspects of Logistics, to ultimately being promoted to the CEO of the US operation. In his time in this role he has improved staff moral while enacting major savings programs.
Before joining SOTIO, Matthew held a series of progressively responsible roles within the American Red Cross. Starting as a laboratory technician, he spent over 17 years working in different areas of the organization until ultimately completing as the interim CEO of the Massachusetts Region.
Although his career was initiated in the laboratory, Matthew has spent his time expanding his knowledge of business and management. He is a graduate of UMass with a degree in Human Resource Management (Summa Cum Laude) and then went on to Eastern Nazarene College to earn a Master’s of Science in Management. He is passionate about his work and enjoys mentoring up-and-coming staff.
Matt co-founded Veeva Systems in 2007 and has been instrumental in building the company into a global market leader, recognized for product excellence and superior customer success. After holding various roles during the company's growth, Matt is responsible today for strategy, alliances and business development, and is a key executive contact for many of Veeva's customers.
Before founding Veeva, Matt held various executive roles at small healthcare technology companies in product management, marketing and business development. Prior to that, Matt was the General Manager of the Pharmaceuticals & Biotechnology division at Siebel Systems, which has since been acquired by Oracle. At Siebel, he was responsible for market leading applications in Pharma CRM and clinical trial management. In 2007, Matt was named to the PharmaVOICE 100, which recognizes the 100 most influential people in the life sciences industry.
Matt currently serves on the Advisory Board at Crossix, an innovator in the healthcare analytics arena. Matt received his MBA from the Harvard Business School, with honors, and his B.A. in Economics from Yale University, cum laude.
Michael Kauffman co-founded Karyopharm Therapeutics Inc. (NASDAQ: KPTI) in Newton, MA, with Dr. Sharon Shacham in 2008 and has served as the Company’s Chief Executive Officer since January, 2011 and as a director since 2009. Prior to joining Karyopharm, he was the chief medical officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc., where he lead the development of carfilzomib (Kyprolis®), a novel proteasome inhibitor, which received accelerated approval in refractory myeloma in 2012 (and full approval since). Dr. Kauffman was an operating partner at Bessemer Venture Partners, where he colead investments in Acceleron (XLRN) and multiple other companies. Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.) from 2002 to 2008. He was the leader of the Velcade® Development Program at Millennium Pharmaceuticals, and held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr. Kauffman is currently on the Board of Directors at Verastem (VSTM), Infinity (INFI), Kezar Biosciences and Karyopharm. Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School and trained in internal medicine and rheumatology at Beth Israel (now BIDMC) and Massachusetts General Hospitals. He is board certified in internal medicine.
Nancy, a veteran in the biopharmaceutical industry, is passionate about bridging the rapids from clinical R&D to life saving and enhancing treatments for patients. She brings deep industry knowledge in leading companies that commercialize a broad range of successful BioPharmaceutical products. She recently joined pSivida, a sustained release drug delivery company focused on diseases of the eye, in September 2016 as President and Chief Executive Officer. Prior to joining pSivida, Ms. Lurker was President and CEO at PDI a leading commercialization and contract sales company that commercialized hundreds of pharmaceutical drugs, devices, OTC and diagnostic tests. In 2015, Nancy led the sale of PDI’s contract sales division to Publicis Touchpoint Solutions.
Prior to joining PDI, she was Senior Vice President and Chief Marketing Officer for Novartis Pharmaceuticals Corporation where she oversaw a $6 billion product portfolio in multiple therapeutic areas, including cardiovascular, CNS, respiratory and anti-infectives. .
Ms. Lurker graduated magna cum laude with a BS in biology from Seattle Pacific University, and holds an MBA from the University of Evansville (Evansville, IN).
Nancy also serves on the Board of Cancer Treatment Centers of America, a multi-billion dollar private cancer treatment hospital system, and is a member of the Novo Advisory Group.
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this, he served as Senior
Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he
served as Group Executive Vice President, Global Business Development and Chief Strategy
Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining, Teva he spent five years as
Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life
sciences venture capital arm of TPG Capital. From 2004-2009, Mr. Sekhri was Founder, President,
and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr.
Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global
Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri
also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic
areas upon which the company would focus. His first role at Novartis was as Global Head, Early
Commercial Development - a department he established to ensure the differential competitive
advantage of Novartis' pipeline.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of
Medicine, where he also received his BS in Zoology.
Mr. Sekhri has been a Director on more than 20 private and public company Boards, and is
currently a member of the Board of Directors of Veeva Systems Inc., and Enumeral Biomedical
Holdings, Inc.; Mr. Sekhri is also the Chairman of the Board of Pharming N.V., Petra Pharma, and
Topas Therapeutics GmbH.
Additionally, he serves on several non-profit Boards including the BioExec Institute, Inc., the TB
Alliance, Young Concert Artists, Inc., The English Concert in America (TECA), and the Caramoor
Center for Music and the Arts. Mr. Sekhri also served as a Member of the Board of Trustees of
Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Mr. Daly has over 25 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. Mr. Daly is Chairman and CEO of Neuralstem, Inc and emerging biotechnology company with clinical programs in the CNS space. In the past he was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca. During his 13-year tenure at Takeda Pharmaceuticals, he served as Executive Vice President with P&L responsibility for businesses across the U.S., Canada, and Central/South America. Earlier in his career, he served in the sales organizations at Merrell-Dow Pharmaceuticals (now part of Sanofi) and TAP Pharmaceuticals (formerly a division of Abbott Labs) in sales, marketing, operations and senior leadership positions at TAP and Takeda. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals (Nasdaq: CPRX) and Synergy Pharmaceuticals (Nasdaq: SGYP). Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University’s Kellogg School of Management.
Ron Squarer has served as Chief Executive Officer and a member of the Array Board of Directors since April 2012. Mr. Squarer has extensive commercial, development and executive leadership expertise from a greater than two decade career in the biopharmaceutical industry. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as Senior Vice President, Chief Commercial Officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer currently serves as a member of the Board of Directors of Retrophin, Inc. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree in biochemistry from the University of California, Berkeley.
Dr. McCarthy joined CytomX in December 2010 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now Merck Palo Alto) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of large pharma partnerships as Vice President Business Development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006 (NASDAQ: SGXP). Immediately prior to joining CytomX Dr. McCarthy was a transactional partner at Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including Afferent Pharmaceuticals (acquired by Merck), TyRx (acquired by Medtronic), Lumena (acquired by Shire), CoLucid (NASDAQ: CLCD) and LEAD Therapeutics, the originator of talazoparib, now a Phase 3 product candidate in the Medivation pipeline. Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King’s College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.
Shabbir Dahod is CEO, co-founder and president of TraceLink, a company focused on helping pharmaceutical manufacturers, distributors and pharmacies deliver safe prescription medicines to patients everywhere through the World’s Largest Track and Trace Network in the Life Sciences industry.
Over the course of his 30 year career, Shabbir has remained on the cutting edge of innovation and focused on the intersection of technology, business, and management. Shabbir has partnered with pharmaceutical manufacturers, wholesalers, pharmacies, regulators, the MIT Auto-ID Lab and partners, to embark on a personal mission to protect patients from the scourge of counterfeit drugs while enabling health through improved access to quality medicine.
Prior to TraceLink, Shabbir founded SupplyScape Corporation in 2003 where he served as CEO and President.
For a decade before SupplyScape, Shabbir worked with Paul Allen, co-founder of Microsoft, at his Seattle-based startup, Asymetrix. While there, Shabbir established Asymetrix as a leader in Multimedia Authoring technology in the Computer Based Learning market. Shabbir incubated and researched multiple emerging web-based products and technologies in conjunction with Paul Allen, including early initiatives in eCommerce, natural language query, online sports, digital media, and Java development tools. He served as a Senior Executive of the Paul Allen group of companies. Shabbir later joined Microsoft as a Senior Leader to lead collaboration and knowledge management efforts using emerging XML standards and new Internet communication tools.
In 1999, Shabbir returned to Boston and founded iWant, serving as President and Chief Executive. He then became involved with the MIT Auto-ID Lab, working closely with Sanjay Sarma to further work on the “Internet of Things” or IoT by determining how to apply RFID to physical objects. This research turned into the founding of Supply Scape and eventually, TraceLink.
Shabbir received a BA in Computer Science from Boston University (’85).
Steve joined SAGE as CMO in 2013. Steve is a former practicing psychiatrist and previously served as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division of AstraZeneca Pharmaceuticals. At AstraZeneca, he also served as the Chair of the Neuroscience Safety Knowledge Group. During his time at AstraZeneca, Steve served as the Medical Science Senior Director for the neuroscience established brands and emerging anesthesia group product team and in other positions of increasing responsibility in the neuroscience discovery medicine, early and late development groups. Prior to joining AstraZeneca, he was a faculty member in the psychiatry department at the University of Pennsylvania School of Medicine, where he continues to serve as an adjunct assistant professor of psychiatry. Steve has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry.
Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.
Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.
Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences, Inc., and the founder and former Chief Executive Officer of Axovant Sciences, Inc. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences Ltd., Myovant Sciences Ltd., and Roivant Sciences Ltd. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.
Yuval Cohen, Ph.D., joined Corbus in July 2013 as Chief Executive Officer. Prior to joining Corbus, he was the President and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Under Dr. Cohen's leadership, Celsus successfully developed five novel anti-inflammatory drug programs - including two in Phase II - focusing on allergies and autoimmune diseases of the skin, airways, digestive tract and eye. He participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fund raising. In March 2013, Dr. Cohen successfully completed a public listing of Celsus in the United States. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. He attained a Bachelor of Science (Honors) from the University of Cape Town (South Africa) before being awarded the prestigious BGF Scholarship from the French foreign ministry to carry out his doctoral studies in Paris.
Cliff co-founded Cornerstone Search Group (Cornerstone) in 2000. He is a Managing Partner of the firm and actively leads and conducts executive search assignments for small, medium and large global pharmaceutical and biotechnology companies.
In addition to managing the day-to-day activities of Cornerstone, Cliff also heads-up Cornerstone’s MD/Physician specialty practice area that fills key positions that require and/or highly prefer MDs/Physicians for positions in the following areas:
Leadership (CxO, Global TA Heads, Global Functional Heads etc.)
Clinical Development for both early Phase 1/FIH through Phase 2/PoC development programs, and later-stage Phase 3/registrational development programs
Medical Affairs (pre-launch planning, launch and lifecycle management)
Drug Safety/Pharmacovigilance/Risk Management
Cliff has successfully planned, conducted and filled multiple Retained Searches at all levels in Cornerstone’s areas of emphasis and expertise, which include the following:
Health Economics and Outcomes Research (HEOR)
Cliff started his career in the executive search industry in 1983. Prior to working in the executive search industry, Cliff worked as a Certified Public Accountant (CPA) for a Fortune 500 Company (Duke Energy), a Top-tier Global Management Consulting Firm (Booz | Allen | Hamilton) and a prominent Certified Public Accounting Firm (Wiss & Company, LLP)
Cliff is a graduate of Montclair State University where he earned a BS degree in Business Administration and a BA degree in Economics.
Cliff is a charter and active member of the International Retained Search Associates organization (IRSA) that is a global executive search organization with 31 offices located throughout the US, Canada, EU, China and Malaysia. He is the past President of the New Jersey Chapter of ACRP (Association of Clinical Research Professionals).
Corey Ackerman, JD, is a Senior Partner with Cornerstone Search Group, a life-sciences executive search firm headquartered in Parsippany, NJ that partners with Pharmaceutical and Biotech companies to identify, recruit, and hire professionals for their US and globally-based Director, VP, and C-level positions. Corey, who has been with Cornerstone since 2001, both actively leads and conducts retained search assignments, as well as provides his clients with strategic advice on organizational structure, talent acquisition/retention strategies, and compensation/benefit guidance. Corey earned his JD (Labor Law focus) from Hofstra University, and earned his BA from Tufts University, where he double majored in Economics and International Relations.
Eugene Babenko is an established pharmaceutical executive with more than 20 years of experience in the pharmaceutical arena. Eugene brings an extensive wealth of knowledge in specialty pharmaceuticals and in various niche therapeutic areas.
Eugene spent 12 years working in a variety of capacities at various major pharmaceutical companies, including GlaxoSmithKline, Novartis and Gilead Sciences, Inc. Ten years ago, he along with 2 partners, founded Quality Specialty Pharmacy (QSP), a successful retail specialty pharmacy chain focusing on disease states such as dermatology, HIV, and hepatitis B and C. QSP's focus is customer-driven and provides affordable, high-quality care for complex chronic conditions. The company prides itself on its commitment to compassion, integrity and quality - measuring its success through healthy outcomes, satisfied clients and clarity of vision to support the hundreds of new life-changing biopharmaceutical drugs that will help patients in the decades to come. QSP is currently licensed and operating in 45 states.
Mikhail joined Atlant Clinical in 2012 as Chief Executive Officer and as a member of the Board of Directors. Prior to Atlant Clinical he worked at GlaxoSmithKline where he started as a clinical research assistant, later becoming a local study manager in the oncology group. He subsequently joined the Moscow Sales Department, where he rose to become Regional Market Access Director. Mikhail graduated from Lomonosov Moscow State University with Master degrees in biochemistry and management.
Noah M. Leibowitz is a Partner in Simpson Thacher’s Intellectual Property Group and Litigation Department. Noah has a special focus on litigation and regulatory issues affecting the pharmaceutical, biotechnology and healthcare industries. His experience includes leading trial teams as first-chair counsel in multiple patent jury trials, as well as negotiating complex collaboration, development and license agreements and advising on merger and acquisition transactions and securities offerings.
In his litigation practice, Noah has represented Daiichi Sankyo in Hatch-Waxman challenges to Daiichi’s patents on its Levaquin®, Benicar®, Benicar® HCT and Azor® products. He has also litigated cases over the well-known Cabilly patents, related to antibody manufacture, in connection with Human Genome Science’s Benlysta® and Eli Lilly’s Erbitux®. Noah has also represented clients in arbitrations related to drug development, clinical trial programs, and FDA inspections and investigations.
On the transactional side, Noah has participated in well over 100 consummated or contemplated transactions and offerings, many involving companies in the healthcare and pharmaceutical industries, including Abbott Laboratories, Accellent, Aisling Capital, Alvogen, Atricure, Boston Scientific, Cardinal Health, CSL Limited, Endo Pharmaceuticals, Galen Holdings, Gland Pharma, Indevus Pharmaceuticals, Lexicon Pharmaceuticals, Link Spine Group, MedAssets-Precyse, NantPharma, PPD, Press Ganey, Q-Med, Stiefel Laboratories, Veracyte and ZS Pharma.
Noah received his A.B. in Biology and Psychology from Columbia University and his J.D. from Columbia Law School. Noah has been consistently recognized by SuperLawyers since 2011, first as a Rising Star and since 2013 as a top Intellectual Property Litigation attorney in the New York Metro area.
This event starts on May 22nd at 12:00 PM.